Form 4: Aquestive Therapeutics Director Receives Stock Options

Director Timothy E. Morris was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director Timothy E. Morris received a grant of 50,500 stock options on June 10, 2026.
• The options have an exercise price of $3.99 per share.
• The options are scheduled to vest in full on June 10, 2027, contingent upon continued service.
• The options expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• Standard retention mechanism for board members.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of equity compensation for a director.

Industry Context

StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The use of time-based vesting (one-year cliff) is consistent with standard industry practices for non-employee director compensation.
• The grant size is typical for mid-cap and small-cap pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised in the future.

Next Steps

• Director to remain in service through June 10, 2027, to satisfy vesting requirements.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Director Compensation, Stock Options, Insider Transaction